CA3164063A1 - Methods of treating splenomegaly - Google Patents

Methods of treating splenomegaly Download PDF

Info

Publication number
CA3164063A1
CA3164063A1 CA3164063A CA3164063A CA3164063A1 CA 3164063 A1 CA3164063 A1 CA 3164063A1 CA 3164063 A CA3164063 A CA 3164063A CA 3164063 A CA3164063 A CA 3164063A CA 3164063 A1 CA3164063 A1 CA 3164063A1
Authority
CA
Canada
Prior art keywords
weeks
human subject
bid
btk inhibitor
myelofibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3164063A
Other languages
English (en)
French (fr)
Inventor
Wayne Philip Rothbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telios Pharma Inc
Original Assignee
Telios Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma Inc filed Critical Telios Pharma Inc
Publication of CA3164063A1 publication Critical patent/CA3164063A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
CA3164063A 2020-01-08 2021-01-08 Methods of treating splenomegaly Pending CA3164063A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08
US62/958,632 2020-01-08
PCT/US2021/012696 WO2021142257A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Publications (1)

Publication Number Publication Date
CA3164063A1 true CA3164063A1 (en) 2021-07-15

Family

ID=76788747

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3164063A Pending CA3164063A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Country Status (15)

Country Link
EP (2) EP3980069A4 (cg-RX-API-DMAC10.html)
JP (2) JP7771064B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220130151A (cg-RX-API-DMAC10.html)
CN (1) CN114423457A (cg-RX-API-DMAC10.html)
AU (1) AU2021205484A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022013646A2 (cg-RX-API-DMAC10.html)
CA (1) CA3164063A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022010592A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220374A (cg-RX-API-DMAC10.html)
IL (1) IL294582A (cg-RX-API-DMAC10.html)
JO (1) JOP20220168A1 (cg-RX-API-DMAC10.html)
MA (3) MA63848B1 (cg-RX-API-DMAC10.html)
MX (1) MX2022008490A (cg-RX-API-DMAC10.html)
TN (1) TN2022000185A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021142257A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12662484B2 (en) 2016-08-17 2026-06-23 Shenzhen Targetrx, Inc. Substituted piperidines as bruton's tyrosine kinase inhibitors
WO2021142257A1 (en) * 2020-01-08 2021-07-15 Telios Pharma, Inc. Methods of treating splenomegaly
US12697333B2 (en) 2020-01-08 2026-08-04 Telios Pharma, Inc. Methods of treating splenomegaly
WO2022266285A1 (en) * 2021-06-16 2022-12-22 Telios Pharma Inc. Treatment of symptoms associated with myeloproliferative neoplasms
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
JP2025527431A (ja) * 2022-08-25 2025-08-22 ビーワン メディシンズ ワン ゲーエムベーハー （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド及びシュウ酸を含む固体形態、その組成物及び使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
SMT202100674T1 (it) * 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
WO2016054491A1 (en) * 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3810590A1 (en) * 2018-06-19 2021-04-28 Merck Patent GmbH Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
CN109942835A (zh) * 2019-03-27 2019-06-28 广州楹鼎生物科技有限公司 一种催化分解木质纤维原料的方法
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
WO2021142257A1 (en) * 2020-01-08 2021-07-15 Telios Pharma, Inc. Methods of treating splenomegaly

Also Published As

Publication number Publication date
CR20220374A (es) 2023-01-25
AU2021205484A1 (en) 2022-08-18
WO2021142257A1 (en) 2021-07-15
EP4000624A1 (en) 2022-05-25
BR112022013646A2 (pt) 2022-10-04
JP7771064B2 (ja) 2025-11-17
CO2022010592A2 (es) 2022-10-31
TN2022000185A1 (en) 2024-04-01
JP2023509968A (ja) 2023-03-10
MA57226A1 (fr) 2023-02-28
MX2022008490A (es) 2022-10-13
EP3980069A1 (en) 2022-04-13
MA69153A1 (fr) 2025-07-31
IL294582A (en) 2022-09-01
MA63848B1 (fr) 2024-10-31
JP2026027353A (ja) 2026-02-18
EP3980069A4 (en) 2022-08-17
KR20220130151A (ko) 2022-09-26
CN114423457A (zh) 2022-04-29
MA57226B1 (fr) 2023-06-28
JOP20220168A1 (ar) 2023-01-30
MA63848A1 (fr) 2024-04-30

Similar Documents

Publication Publication Date Title
EP4000624A1 (en) Btk inhibitors for treating splenomegaly
US20260097028A1 (en) Methods of Treating Myeloproliferative Neoplasms
US20220387434A1 (en) Combination of a btk inhibitor and an mdm2 inhibitor for cancer treatment
AU2019263064B2 (en) Methods of treating cancer
US11642343B2 (en) Methods of treating splenomegaly
CN112165945A (zh) 治疗淋巴样恶性疾病之方法
EP4355431A1 (en) Treatment of symptoms associated with myeloproliferative neoplasms
WO2024124240A1 (en) Methods of treating myeloproliferative neoplasms
HK40078282A (en) Btk inhibitors for treating splenomegaly
US20250387383A1 (en) Methods of treating myeloproliferative neoplasms
HK40112620A (en) Novel use of quinazolinone compound for the treatment of cancer
EA045240B1 (ru) Способы лечения рака
EA049145B1 (ru) Способы лечения миелопролиферативных неоплазий

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240924

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241205

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241205

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241231

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241231

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250711

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251107